CriticalmTOR kinase inhibitor – immunosuppressant and antineoplastic×Selective immunosuppressant, mTOR inhibitor
Updated · Methodology
Mechanism
Both are mTOR inhibitors. Combined use produces dual blockade with severe immunosuppression and toxicity. No clinical indication for co-use.
Symptoms
Severe immunosuppression, infections, pneumonitis.
Management
Combination contraindicated.
Check the full regimen, not just this pair
Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.
Summary of a multi-drug list →
Medicine list: everything you take in one place →
Sources
- FDA: Rapamune (sirolimus) prescribing information (2017)
- AEMPS: Ficha técnica: Everolimus (nº registro 84203), sección 4.4 (2024)– AEMPS, CIMA, nº registro 84203, revisión 09/2024, sección 4.4